Stivarga 40 Mg 40 mg FC tablets
PDF Leaflet Revision Date: 01 June 2020
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma.
Dosage (summary)
160 mg orally once daily for 3 weeks, followed by 1 week off.
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; may cause fetal harm.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- BCRP substrates
Contraindications
- Hypersensitivity to regorafenib
- Pregnancy
- Breastfeeding
- Gastrointestinal perforation
Common side effects
- Hand-foot skin reaction
- Fatigue
- Diarrhea
- Hypertension
- Infection
Counselling Points
- Take with a light meal
- Monitor for liver function abnormalities
- Use effective contraception during treatment
Serious warnings
- Severe liver injury
- Gastrointestinal perforation
- Myocardial ischemia
- Increased risk of hemorrhage
Important Disclaimer
The Stivarga 40 Mg 40 mg FC tablets professional information leaflet below is the property of Bayer and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
